«Money back guarantee» for cell -
gene therapy drug High prices for marketed cell / gene therapy products is a hot and controversial topic.
Not exact matches
Robert Beall becomes CEO of the CFF and, grasping the limitations of
gene therapy, invests $ 3.2 million in Aurora Biosciences Corp., where cell physiologist Paul Negulescu begins to look for a chemical cure using
high - throughput methods to test large numbers of potential
drugs.
Because of their unique properties such as monodispersity, large surface area and
high drug loading efficiency, silica nanoparticles (SiNPs) have been developed for a vast array of biomedical uses such as optical imaging, cancer
therapy, targeted
drug delivery and controlled
drug release for
genes and proteins.